Molecular detection of TP53, Ki-Ras and p16INK4A promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study

Annals of Oncology

Volumn 17, Issue SUPPL. 7, 2006, Pages

  Bazan, V ^a   Bruno, L ^a   Augello, C ^a   Agnese, V ^a   Calo V ^a   Corsale, S ^a   Gargano, G ^a   Terrasi, M ^a   Schiro V ^a   Di Fede, G ^a   Adamo, V ^b   Intrivici, C ^a   Crosta, A ^a   Rinaldi, G ^a   Latteri, F ^a   Dardanoni, G ^e   Grassi, N ^a   Valerio, M R ^a   Colucci, G ^c   Macaluso, M ^d   Russo, A ^a   more..

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d TEMPLE UNIVERSITY   (United States)

^e Epidemiological Observatory Center of Sicilian Region   (Italy)

Author keywords

Colorectal carcinoma; Free cell DNA; Ki Ras; TP53

Indexed keywords

K RAS PROTEIN; PROTEIN P16INK4A; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RELAPSE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DNA DETERMINATION; DNA METHYLATION; FEMALE; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENETIC CODE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON INVASIVE MEASUREMENT; ONCOGENE K RAS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TUMOR SUPPRESSOR GENE;

AGED; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENES, P16; GENES, P53; GENES, RAS; HUMANS; MALE; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES;

EID: 33745622160     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl958     Document Type: Article

References (20)

1. Boyle P. Some recent developments in the epidemiology of colorectal cancer. In Bleiberg H, Rougier P, Wilke H-J (eds): Management of Colorectal Cancer. London: Martin Dunitz 1998; 19-34.
2. Lecomte T, Berger A, Zinzindohoue F et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002; 100: 542-548.
3. Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res 2002; 22: 421-425.
4. Ikeguchi M, Ohro S, Maeda Y et al. Detection of cancer cells in the peripheral blood of gastric cancer patients. Int J Mol Med 2003; 11: 217-221.
5. Russo A, Bazan V, Agnese V et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53 CRC collaborative studies. Ann Oncol 2005; 16 (Suppl 4): Iv44-iv49.
6. Esteller M, Gonzalez S, Riques RA et al. K-Ras and P16 Aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299-304.
7. Nakayama H, Hibi K, Taguchi M et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett 2002; 188: 115-119.
8. La Farina M, Maturi N, Stira S et al. Direct identification of each specific mutation in codon 12 and 13 of ci-ki-ras2 by SSCP analysis. Biochem Biophys Res 1998; 246: 813-815.
9. Russo A, Migliavacca M, Zanna I et al. p53 Mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: A prospective study with a five-year follow-up. Cancer Epidemiol Biomarkers Prevention 2002; 11: 1322-1331.
10. INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas. J Cell Physiol 2006; 207: 654-659.
11. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665.
12. Ryan BM, Lefort F, McManus R et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: Strong prognostic indicator in postoperative follow up. Cancer 2003; 52: 101-108.
13. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastas 1999; 18: 65-73.
14. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994; 265: 346-355.
15. Van Rijnsoever M, Grieu F, Elsaleh H et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG Islands. Gut 2002; 51: 797-802.
16. Yang HJ, Liu VWS, Wang Y et al. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 2004; 93: 435-440.
17. Ito T, Kaneko K, Makino R et al. Clinical significance in molecular detection of p53 mutation in serum of patients with colorectal carcinoma. Oncol Rep 2003; 10: 1937-1942.
18. Yang HJ, Liu VW, Wang Y et al. Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol Oncol 2004; 93: 435-440.
19. Dabritz J, Hanfler J, Preston R et al. Detecton of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer 2005; 92: 405-412.
20. Ito S, Hibi K, Nakayama H et al. Detection of tumor DNA in serum of colorectal cancer patients. J Cancer Res 2002; 93: 1266-1269.